Next-Generation Bio-Sensing Platform for

Gemina Labs has developed and patented a transformative bio-chemistry that powers next-generation testing platforms for detecting a wide range of pathogens that affect humans and animals. Our tests are fast, affordable and accurate, and easily self-administered providing consumers with direct solutions where they need them.

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Company Highlights

Market
With speed, affordability, and accuracy at the center of Gemina’s technology, the market opportunities in diagnostics range from applications like in-vitro diagnostics for human health ($83 BN) to the contract cleaning services market ($292 BN).
Team
Gemina’s team is comprised of industry-leading experts in the research, development, and commercialization of biotechnologies.
Innovative Technology
Watch how Gemina’s next-gen biosensing unlocks entry in multiple markets via an innovative platform for pathogen detection that is a simple, affordable, effective, and non-invasive antigen test that returns results in minutes, coupled with a digital risk management system.
Intellectual Property
Gemina is a world-leading developer of novel surface binders, which are the key to enabling the speed, affordability, and accuracy of our platform for pathogen detection.
Democratizing Diagnosis
The keys to democratize access to diagnosis are speed, affordability, and accuracy. Gemina’s next-generation platform unlocks the opportunity.
Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

What the Experts Say

The Gemina Labs dual affinity probe technology establishes a flexible and novel approach to attaching functional biomolecules to diverse surfaces …The technology has been evaluated by Paragreen and offers significant potential competitive advantages including increased performance and cost efficiency in applications ranging from human and veterinary diagnostics to environmental testing, food safety, agriculture, and industrial bioprocessing.”
Prof. Mike Catt, Paragreen Associates, and inventor for the Clearblue® pregnancy test
Stay Informed

The Testing Platform Powering the Future

Traditional

  • Single function
  • Qualitative result (ie. Yes/No)

The Future with Gemina

We're building a new category of biosensors - moving diagnosis out of the clinic and into the hands of the patient and user...

Multi-Function Tests

We are creating a future where taking one test will tell you more than whether you are infected or not. What if one test could tell you whether you have Influenza...or Covid, or neither? Powered by Gemina's chemistry, we are developing affordable, disposable "Multiplexed" testing devices.

Quantitative Results

We are building a future where tests are more than "+ve" or "-ve" results. Gemina devices will deliver values that enable the daily monitoring of wellbeing and chronic conditions.

Digital Integration

Results can go straight to Testpoint, Gemina's digital smartphone application, and integrate into other data systems (healthcare providers, employer, etc.)

BEYOND HUMAN HEALTH

Gemina's product development roadmap goes beyond direct human health and wellbeing applications. Our technology will be used in sectors by proactively testing to protect human health.

A Deep Bench of Expertise

Gemina’s team is comprised of industry-leading experts in the research, development, and commercialization of biotechnologies.

Team

John Davies, CEO

Over 25 years experience and over 100 IP commercializations in Europe and Canada. Founding member of LSE listed IP Group (LON:IPO), former CEO of Scientific Research Capital. Trained in law at Oxford University, and qualified as an accountant in the UK.

Rob Greene, CTO

Scientific founder and lead researcher, with 20 years of commercial and laboratory research in surface chemistry applications in medical technology and mining. Master's in Chemistry from UBC.

Mike Liggett, CFO

Original training in Pharmaceutical Sciences in addition to Chartered Accountant designation. Spent 7 years with Price Waterhouse Coopers, and has accumulated more than 20 years experience in public company CFO roles.

Dr. Christine Buerki, Head of Chemistry

Highly experienced research and commercial scientist with a PhD in molecular biology and immunology from University of Zurich. 14 years of commercial experience in biotechnology companies.

Dr. Mike Kennedy, Head of Digital

Serial entrepreneur, building on a PhD in Management Information Systems and the University of Washington. Appointed as Research Fellow at UBC’s Urban Data Lab.

David Browning, Head of Wellness Applications

Senior scientist and product developer with over 40 years of experience in life science product management with companies including Phillips, Kodak Clinical Products, J&J Diagnostics and IGEN.

Clint Undseth, Head of Hygiene Applications

Highly experienced business development professional. Former VP Innovation with Stuart Olson building on BD roles with AMP, IBM, PURUS.

Board of Directors

Dr. James Tansey

Experienced entrepreneur and professor at the Sauder School of Business. Founder of Centre for Social Innovation and Impact Investing and CEO of Canvas Impact Advisors. Global authority on impact investing and active in the Creative Destruction Lab.

Rob Greene

Scientific founder and lead researcher, with 20 years of commercial and laboratory research in surface chemistry applications in medical technology and mining. Master's in Chemistry from UBC.

John Davies

Over 25 years experience and over 100 IP commercializations in Europe and Canada. Founding member of LSE listed IP Group (LON:IPO), former CEO of Scientific Research Capital. Trained in law at Oxford University, and qualified as an accountant in the UK.

Martin Cronin

Senior executive with over 20 years experience in international diplomacy with the British Government. Extensive international relationships at corporate and government levels. Served as CEO and Director of companies including Patriot One (TSX:PAT) and Helios Global.

David Rokoss

More than 20 years experience in capital markets and business development across multiple sectors. Experience in due diligence, local and cross-border mergers, corporate acquisitions, and compliance issues, having worked with companies in multiple jurisdictions including those publicly trading in Canada, the United States, and Germany.

Advisors

Dr. Mike Catt

Professor and Turing Fellow, Newcastle University. Career in vitro diagnostic product development (Swiss Precision, Unilever) including pioneering the development of the Clearblue lateral flow assay pregnancy test. At Unilever he led the Healthy Aging program for integrated technologies for lifestyle interventions.

Andrew Rae

Early career as a biotech analyst, launched career as an executive and board positions in biotechnology companies in Canada and the US. Responsible for commercial transactions with Alexion Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, and JDR.

Shameze Rampertab, MBA, CPA

Over 20 years experience in the healthcare sector with a variety of corporate leadership roles, including Asensus Surgical, Zomedica, Profound Medical and Intellipharmacetics. Experienced investment banker and sell-side equity research analyst.

Hugh MacNaught

Executive with thirty years experience in Fortune 100 companies in the development of life science technologies. Worked in product development with Amersham, Kodak Diagnostics, Boehringer Mannheim and others. Background includes extensive experience in clinical diagnostics, therapeutics and diagnostic imaging.

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.